Literature DB >> 10923615

Catalytic inhibition of topoisomerase II in Werner's syndrome cell lines enhances chromosomal damage induced by X-rays in the G2 phase of the cell cycle.

A Franchitto1, P Pichierri, P Mosesso, F Palitti.   

Abstract

PURPOSE: To investigate whether catalytic topoisomerase II activity by ICRF187, a compound that interferes with the catalytic cycle of topoisomerase II without causing DNA damage, could result in a modulation of X-ray-induced chromosomal damage in Werner's syndrome (WS) cell lines.
MATERIALS AND METHODS: Two WS (KO375, DJG) and one normal lymphoblastoid cell line (SNW646) were exposed to X-rays, post-treated with ICRF187 and harvested after various recovery times. Cell progression to mitosis was monitored by 5-bromo-2'-deoxyuridine (BrdUrd) and fluorescent immmunodetection to analyse chromosomal damage in homogeneous treated cell populations in the G1, S or G2 phase of the cell cycle.
RESULTS: In WS cell lines, catalytic inhibition of topoisomerase II activity by ICRF187 resulted in potentiation of X-ray- induced chromosomal damage in the G2 phase of the cell cycle. This potentiation was not observed in the G1 or S phases of the cell cycle, neither in WS nor normal cells.
CONCLUSION: These results point out the possibility that Werner's syndrome protein (WRNp) might play a role in a G2 recombinational pathway of double-strand break repair, cooperating with topoisomerase II and thus contributing to maintain genomic integrity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923615     DOI: 10.1080/09553000050050927

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  2 in total

1.  Comparison of the antimutagenic activities of natural and synthetic substances in irradiated repair-defective human cells.

Authors:  G D Zasukhina; A N Semyachkina; I M Vasil'eva; A I Vedernikov; S P Gromov; M V Alfimov
Journal:  Dokl Biol Sci       Date:  2006 May-Jun

2.  The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.

Authors:  Federico Innocenti; Snezana Mirkov; Ramamoorthy Nagasubramanian; Jacqueline Ramírez; Wanqing Liu; Wasim K Bleibel; Sunita J Shukla; Kathleen Hennessy; Gary L Rosner; Edwin Cook; M Eileen Dolan; Mark J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  2008-08-02       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.